LEADER 01340nas 2200493-a 450 001 996535172703316 005 20230518213020.0 035 $a(OCoLC)137349884 035 $a(CKB)5590000001065312 035 $a(CONSER)--2011267057 035 $a(EXLCZ)995590000001065312 100 $a20751101a19449999 k-- - 101 0 $afre 135 $aur|n||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 13$aLe monde 210 1$aParis :$cImp. sp. du "Monde" 215 $a1 online resource 311 $a0395-2037 531 0 $aMonde 606 $aFrench newspapers$zFrance$zParis 606 $aJournaux français$zFrance$zParis 606 $aFrench newspapers$2fast$3(OCoLC)fst00934758 606 $aZeitung$2stw 606 $aFrankreich$2stw 607 $aParis (France)$vNewspapers 607 $aFrance$zParis$2fast 608 $aPeriodicals.$2fast 608 $aPeriodical 608 $anewspapers.$2aat 608 $aNewspapers.$2fast 608 $aNewspapers.$2lcgft 608 $aJournaux.$2rvmgf 615 0$aFrench newspapers 615 6$aJournaux français 615 7$aFrench newspapers. 615 7$aZeitung. 615 7$aFrankreich. 906 $aJOURNAL 912 $a996535172703316 996 $aMonde$9457024 997 $aUNISA LEADER 05710nam 2200625 450 001 9910162992903321 005 20170924185125.0 010 $a3-318-05565-4 035 $a(CKB)3880000000024112 035 $a(EBL)4395885 035 $a(SSID)ssj0001572487 035 $a(PQKBManifestationID)16218125 035 $a(PQKBTitleCode)TC0001572487 035 $a(PQKBWorkID)14836250 035 $a(PQKB)10156662 035 $a(MiAaPQ)EBC4395885 035 $a(SZ-BaSKA)266819 035 $a(PPN)198105789 035 $a(OCoLC)928629663 035 $a(EXLCZ)993880000000024112 100 $a20150619h20162016 uy| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aRetinal pharmacotherapeutics /$fvolume editors, Quan Dong Nguyen [and four others] 210 1$aBasel ;$aNew York :$cKarger,$d[2016] 210 4$dİ2016 215 $a1 online resource (426 p.) 225 1 $aDevelopments in ophthalmology,$x0250-3751 ;$vvolume 55 300 $aPreceded by Retinal pharmacotherapy / [edited by] Quan Dong Nguyen [and others]. 2010. 311 $a3-318-05564-6 320 $aIncludes bibliographical references and index. 327 $aCover; Retinal Pharmacotherapeutics; Contents; List of Contributors; Foreword; Evolving Knowledge in Pharmacologic Treatments of Age-Related Macular Degeneration; Abstract; The Drugs; Routes of Administration; Conclusion; References; Retinal Anatomy and Pathology; Abstract; Normal Retinal Anatomy; Retinal Pathology; Conclusion and Implications for Retinal Pharmacotherapy; References; Retinal Biochemistry, Physiology and Cell Biology; Abstract; Vitreous Biochemistry; Blood-Retinal Barrier; Retinal Blood Flow and Vascular Caliber; Macular Pigments; Apoptosis and Retinal Degeneration 327 $aVisual CycleRetinal Pigment Epithelium and Lipofuscin; Matrix Biology; References; Ocular Angiogenesis: Vascular Endothelial Growth Factor and Other Factors; Abstract; Promoters of Angiogenesis; Investigational Approaches; Conclusion; Acknowledgments; References; Ocular Immunity and Inflammation; Abstract; History; Key Concepts and Fundamentals in Molecular Biology and Biochemistry; Mechanisms of Pathogenesis; Implications for Retinal Pharmacotherapy; Key Points; References; Complement Activation and Inhibition in Retinal Diseases; Abstract; History; Key Concepts in Complement Biology 327 $aPathogenic Mechanisms and MetabolismImplications for Retinal Pharmacotherapy; Conclusion; References; Genetics in Retinal Diseases; Abstract; Retinal Disease Genes; Retinitis Pigmentosa: A Monogenic Disorder; Molecular Diagnosis and Gene Therapy of Monogenic Retinal Dystrophy; Age-Related Macular Degeneration - A Multifactorial Disease; Treatment of Age-Related Macular Degeneration; References; Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections; Abstract; Rationale for Intravitreal Drug Administration; Key Concepts in Retinal Drug Delivery 327 $aStrategies and Implications for Retinal Pharmacotherapy: Preoperative PreparationProphylaxis of Endophthalmitis: Local Disinfection and Topical Antibiotics; Local Topical Anesthesia; Recommended Surgical Techniques for Retinal Drug Delivery; Complications Associated with the Drug Delivery Route; Incidence of Endophthalmitis and Topica lAntibiotics; Postoperative Ocular Complications; Pharmacokinetics and Clearance of Intravitreal Drugs; Conclusion; References; Routes for Drug Delivery to the Retina: Topical, Transscleral, Suprachoroidal and Intravitreal Gas Phase Delivery; Abstract; History 327 $aKey ConceptsAnimal Models; Drug Delivery Modalities; Future Directions and Technologies; Conclusion; Acknowledgment; References; Routes for Drug Delivery: Sustained-Release Devices; Abstract; History; Key Concepts and Fundamental Points in Sustained-Release Drug Delivery; Existing Sustained-Release Drug Devices; Biodegradable Polymer Implants; Liposome Encapsulation; Micro- and Nanoparticle-Coupled Drug Delivery; Cellular Encapsulation; The Future; Conclusion and Key Points; Acknowledgment; References; Microspheres and Nanotechnology for Drug Delivery; Abstract 327 $aWhat Is Micro- and Nanotechnology? 330 $aThe use of pharmacotherapeutics in the management of retinal diseases is rapidly evolving, and a favorable therapy for the patient. Today anti-VEGF agents are used for a range of indications from inflammation-related choroidal neovascularization to macular edema secondary to retinal vein occlusion or diabetic retinopathy. Beyond VEGF, there is an array of target areas under investigation ? not only for vascular pathologies such as age-related macular degeneration and diabetic eye disease, but also for degenerative, infectious and inflammatory retinal conditions. This publication discusses many aspects from basic research on the retina, to animal models for retinal drug delivery, retinal diseases that are amenable to pharmacotherapy and also drugs and mechanisms in retinal diseases. Anyone concerned with the management of retinal diseases - the general ophthalmologist and the retina specialist alike ? will find this book indispensable reading. 410 0$aDevelopments in ophthalmology ;$vv. 55. 606 $aRetina$xEffect of drugs on 606 $aRetina$xDiseases$xTreatment 615 0$aRetina$xEffect of drugs on. 615 0$aRetina$xDiseases$xTreatment. 676 $a617.7/35061 702 $aNguyen$b Quan Dong 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910162992903321 996 $aRetinal pharmacotherapeutics$92788937 997 $aUNINA